Patent · US Active

6 substituted 2, 3,4,5 tetrahydro-1H-benzo[d]azepines as 5-HT2C receptor agonist

US8580780B2 · kind B2 · utility

0Cited by

3References

21Claims

0Family size

Assignee

ELI LILLY AND COMPANY · US

Inventors

John Gordon Allen · Newbury Park, US
Karin Briner · Indianapolis, US
Christopher Stanley Galka · Carmel, US
Maria Angeles Martinez-Grau · Madrid, ES
Matthew Robert Reinhard · Indianapolis, US
Michael Rodriguez · Arlington Heights, US
Roger Ryan Rothhaar · Reelsville, US
Michael Wade Tidwell · Lakehills, US
Frantz Victor · Indianapolis, US
Deyi Zhang · Carmel, US
Steven A. Boyd · Longmont, US
Arundhati S. Deo · Windom, US
Wai-Man Lee · Sacramento, US
Christopher Stephen Siedem · Boulder, US
Ajay Singh · Princeton, US

Key dates

Filing date	Jul 28, 2011
Grant date	Nov 12, 2013
Priority date	—
Expiry date	Jul 28, 2031

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D417/12
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula I as selective 5-HT2C receptor agonists for the treatment of 5-HT2C associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety:where:

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.